Tag: innovation

Posts with tag: innovation

Latest Posts

Seaboard Corp. profit falls in Q4, 2022

Seaboard Corp. (SEB) reports $154 million profit in Q4, with revenue of $2.48 billion. For the year, the company reported profit of $88 million, with revenue of $9.1 billion.

Nu Skin Enterprises Reports Q4 Loss, Offers Guidance

Nu Skin Enterprises Inc. (NUS) reported a Q4 loss of $36.1 million, or 73 cents per share. Adjusted EPS was 38 cents. Revenue was $445.6 million. Full-year results include a loss of $146.6 million, or $2.95 per share. Revenue was $1.73 billion. For Q1, Nu Skin expects EPS of 10-20 cents, on revenue of $345-$365 million. Full-year EPS is seen in the range of 90 cents to $1.30, with revenue in the $1.48 billion to $1.62 billion range.

SailPoint IPO Raises $1.38 Billion in Public Debut

Top Cybersecurity Stock SailPoint Returns to Nasdaq via IPO Amassing $1.38B

Hims Surges Over 27% After Super Bowl Ad Controversy Over GLP-1 Weight-Loss Drugs

Hims & Hers stock spikes after Super Bowl ad, driven by retail investor interest following Senate approval of Robert F. Kennedy Jr. as HHS secretary.

Air Lease (AL): Q4 Exceeds Expectations, Is It a Buy?

Air Lease (NYSE:AL) exceeded Q4 CY2024 expectations, beating revenue estimates by 1.6% and EPS by 12.2%. Despite flat year-on-year sales, analysts expect 11.1% growth in the next 12 months. Learn more in our full research report on Air Lease's fundamentals, valuation, and investment potential.

Linda McMahon Vows to Continue Public Service Loan Forgiveness

Education Secretary nominee Linda McMahon pledges to continue popular Public Service Loan Forgiveness program despite potential pressure from within the Trump administration. Despite criticism and attempts to eliminate the program in the past, McMahon affirms her commitment to honoring existing laws that grant loan forgiveness for government and nonprofit service.

Hims & Hers Stock Jumps on Telehealth Weight-Loss Drug Controversy

Hims & Hers stock surges after Super Bowl ad promoting affordable weight-loss drugs sparks controversy and attracts attention from Congress and the new HHS secretary.

Morgan Stanley Boosts X Holdings Debt Offering to $4.74 Billion

Morgan Stanley boosts the size of its latest debt offering for X Holdings to $4.74 billion, indicating strong investor appetite and a significant shift in perception about the company's prospects.

High-Yield Savings Accounts vs. 401(k)s: What to Know

Not sure where to park your retirement savings? Compare high-yield savings accounts (HYSAs) vs. 401(k)s, including key differences, benefits, and why a 401(k) may be a better choice for long-term retirement goals.

Arm to Launch Own Chip, Shift to Direct Manufacturing

Chip designer Arm is reportedly planning to release its first in-house chip this year, with Meta among its early customers.